METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Clinical trials for METASTATIC BREAST CANCER ( HER2 NEGATIVE) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC BREAST CANCER ( HER2 NEGATIVE) trials appear
Sign up with your email to follow new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat breast cancer: drug duo targets rare mutation
Disease control Recruiting nowThis study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is…
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Blood test could personalize breast cancer treatment
Disease control Recruiting nowThis study explores whether changes in a blood-based tumor marker (ctDNA) can help doctors decide the best treatment for people with HER2-negative metastatic breast cancer. Participants first receive a standard antibody-drug combination therapy. Based on how much the ctDNA level …
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New PET scans could predict who benefits from targeted breast cancer therapy
Knowledge-focused Recruiting nowThis study tests whether two types of PET scans can predict how well a targeted therapy works in people with advanced HER2-negative breast cancer. The therapy, called a TROP2 antibody-drug conjugate, delivers chemotherapy directly to cancer cells. Researchers will scan 45 partici…
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 23, 2026 12:00 UTC